Tag: Pharmacology
-
Preparing for Success
On 10th of March at Jesus College Cambridge, Sygnature Discovery held a seminar on ππ΅π°π³πͺπ¦π΄ π°π§ ππ³πΆπ¨ ππͺπ΄π€π°π·π¦π³πΊ ππΆπ€π€π¦π΄π΄, joined by the Cellestial team Nat Hastings, Lewis Pennicott, and Peter Bach. Examples of rapid development were discussed where lead optimisation to human trial readiness was complete in only 18 months. Programs that utilise time and…
-
Back at it again in Boston
This week, Dr Nat Hastings represented innovative research into astrocyte pathology in Parkinson’s at the 14th Alzheimer’s & Parkinson’s Drug Development Summit on behalf of Cellestial Health at Hyatt Regency Boston Harbor. Astrocytic lineage is one of the most populous cell types in the brain, yet the damage Parkinson’s pathology does to it remains underappreciated.…
-
Topic in Spotlight: Brain Delivery
A drug has to be efficacious, safe, and potent – but first of all, it has to get to the right place. On Thursday 10thΒ of July, the Formulation Adviser to Cellestial Health, Prof Claire Thompson of Agility Life Sciences, presented on the topic of formulation choice for proof-of-concept studies in Parkinson’s models at the Bionow…
-
Strategic Win: Preclinical Development Consultation with L2D
Cellestial Health is one of the preclinical-stage companies that was recently selected for a free consultation with the top experts at Leads to Development (L2D) regulatory consultancy, Jonathan Kearsey and Vincent Dubois. This will provide confidential guidance and advice on the path to the regulatory approval of the first Cellestial drug asset. As Nat Hastings,…
-
OBN BioSeed: Raising Awareness
On Monday 9th of June, Dr Nat Hastings presented the developments and plans of Cellestial Health at the annual #BioSeed event, where pitches are delivered by companies looking for Seed funding. At the moment, Cellestial is only preparing for its Seed funding round. What are the benefits of our early discussion with the investor community?…
-
New Collaboration Alert: o2h Discovery and Cellestial
Cellestial Health joins forces with o2h in drug discovery as an awardee of the latest Kickstrater Award. o2h discovery is a collaborative Contract Research Organisation which has an integrated drug discovery platform in Ahmedabad (India) and Cambridge (UK). o2h offer a multi-modality integrated drug discovery platform to support their collaborators developing the next generation of…
-
Making it Happen: a Path to Commercialisation
What does it take to successfully commercialise healthcare innovation? Excellent science is key, but it is not enough. Many factors must converge for a therapeutic discovery to find its way to practical applications: Dr Chloe Hall spoke with Dr Nat Hastings about translatability of Parkinson’s models and specific challenges that emerging companies face in this…
-
Astrocytes: Equally Important yet Diverse
Are all astrocytes the same in Parkinson’s? Astrocytes represent a brain cell type that is found across all areas of the brain. Depending on the region, they comprise 1/3rd – 2/3rds of all cells, and network coupling is an important feature of all astrocytes. However, multiple differences have been noted among astrocytic populations, both within…
-
Welcome to Cellestial Health
A constellation of brain health innovation! Introducing the new digital home ofΒ Cellestial Health, where every step forward redefines the universe of possibilities in brain health. Join us as we navigate uncharted territories to transform lives and revolutionise brain disease treatments.